Arca
Skip to content
Tools
Tools

ABCB1: ATP-dependent translocase ABCB1

Translocates phospholipids and drugs across the membrane.

  • Drugs that act on it: 5
  • Approved: 0
  • In phases 1 to 3: 5
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on ABCB1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4
  • Protein or peptide 1

Approved0

    Phase 34

    • Encequidar
    • Tariquidar
    • Valspodar
    • Zosuquidar

    Phase 21

    • Biricodar

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Health Hope Pharma120%
      • Kanisa Pharmaceuticals120%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: P-glycoprotein 1 inhibitor.
      EncequidarPhase 3Health Hope PharmaSmall moleculeInhibitor3
      TariquidarPhase 3QLTSmall moleculeInhibitor0
      ValspodarPhase 3—Protein or peptideInhibitor0
      ZosuquidarPhase 3Kanisa PharmaceuticalsSmall moleculeInhibitor0
      BiricodarPhase 2Vertex PharmaceuticalsSmall moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
      A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid TumorsEncequidarPhase 1Not yet recruitingHealth Hope PharmaMay 12, 2026
      Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast CancerEncequidarPhase 3Not yet recruitingHealth Hope PharmaFeb 19, 2025
      I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerEncequidarPhase 2RecruitingQuantumLeap Healthcare CollaborativeJan 5, 2010

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Response to tramadol0.55
      • Encephalopathy, acute transient0.42
      • Non-small cell lung carcinoma0.34
      • Plasma cell myeloma0.28
      • Idiopathic generalized epilepsy0.26

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4302, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P08183, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.